An economic analysis of BPaL for multidrug-resistant TB in South Africa and the Philippines.

BACKGROUND

The WHO endorses bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for multidrug-resistant/rifampicin-resistant TB, and both the Philippines (PH) and South Africa (SA) have adopted these regimens.

METHODS

Using a Markov model, we assessed the cost per successful treatment and 5-year budgetary and economic impact of BPaL-based regimens in SA and PH. Treatment outcomes were informed by national electronic registries, SA BPaL Clinical Access Program, and PH operational research. Costs were estimated from the provider perspective.

RESULTS

Over 5 years, BPaL-based regimens reduce total costs by 20%-25% in SA and 9%-11% in PH compared with a standard short oral regimen (SSOR) when achieving the same number of successful treatments, due to lower cost per successful treatment from reduced loss to follow-up and mortality. BPaL-based regimens improve treatment success by 22%, leading to more patients completing full treatment and higher overall resource use. Therefore, the budget for BPaL-based regimens is projected to increase by 7%-8% (SA) and 6% (PH) from 2023/24 to 2027/28.

CONCLUSION

BPaL-based regimens reduce cost per successful treatment compared with SSOR and require smaller budgets for similar treatment outcomes. Implementation may involve initial budget increases, but improvements in treatment success and long-term health outcomes outweigh these costs, presenting a strong rationale for rollout.